Cue Biopharma Inc. has received pre-IND feedback from the FDA to discuss the proposed development plan for CUE-401, its lead autoimmune asset. Based on FDA feedback, the company intends to file an IND ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results